Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PALI save search
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool
Published: 2024-04-16 (Crawled : 12:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 113.15%
H: 10.29%
C: -32.23%
pali-2108 study
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
Published: 2024-04-11 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 3.69%
H: 15.4%
C: 3.79%
Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™
Published: 2024-04-10 (Crawled : 12:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -6.09%
H: 2.54%
C: -20.04%
pali-2108 for
Palisade Bio Announces 1-for-15 Reverse Stock Split
Published: 2024-04-03 (Crawled : 22:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -2.06%
H: 2.36%
C: 0.66%
Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update
Published: 2024-03-27 (Crawled : 12:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 1.93%
H: 4.03%
C: 4.03%
year update financial results
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Published: 2024-02-15 (Crawled : 13:30) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -3.01%
H: 2.99%
C: 1.45%
disease week
Palisade Bio Provides Corporate Update and Reiterates Guidance
Published: 2024-02-13 (Crawled : 13:30) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -0.22%
H: 0.27%
C: -4.0%
update
Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members
Published: 2024-02-08 (Crawled : 20:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -0.6%
H: 1.54%
C: -1.59%
Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
Published: 2024-02-08 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -3.39%
H: 6.83%
C: 4.51%
key leaders
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
Published: 2024-01-30 (Crawled : 14:30) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -25.0%
H: 8.83%
C: -13.35%
million
Palisade Bio Announces Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn’s & Colitis Congress
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 125.0%
H: 27.35%
C: -17.95%
pali-2108 congress positive preclinical program
Palisade Bio Selected for Poster Presentation at the 2024 Crohn’s & Colitis Congress
Published: 2024-01-09 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 1.22%
H: 2.41%
C: 0.19%
congress presentation
Palisade Bio Announces Receipt of Second Milestone Payment from the US Crohn’s and Colitis Foundation for Development of PALI-2108
Published: 2023-12-28 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 8.33%
H: 7.62%
C: 0.6%
pali-2108 payment milestone
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
Published: 2023-11-10 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 2.88%
H: 0.0%
C: -0.93%
business financial results
Palisade Bio to Participate at the Virtual Investor Ask the CEO Conference
Published: 2023-10-11 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 0.0%
H: 0.02%
C: -1.96%
ceo conference
Palisade Bio Announces Closing of $2 Million Registered Direct Offering Priced At Market Under Nasdaq Rules
Published: 2023-09-11 (Crawled : 20:00) - palisadebio.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -1.21%
H: 0.0%
C: -4.33%
nasdaq direct offering market
Palisade Bio Appoints GI Clinical Expert and Biotech Entrepreneur Mitchell Jones, M.D., Ph.D. as Chief Medical Officer
Published: 2023-09-11 (Crawled : 12:30) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -4.64%
H: 6.94%
C: 1.39%
biotech medical
Palisade Bio Announces $2 Million Registered Direct Offering of Common Stock Priced At Market Under Nasdaq Rules
Published: 2023-09-07 (Crawled : 13:00) - palisadebio.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -39.58%
H: 6.78%
C: -10.37%
nasdaq direct offering market
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
Published: 2023-09-06 (Crawled : 13:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: 79.79%
H: 55.65%
C: 16.13%
drug disease worldwide pipeline agreement
Palisade Bio Reports Second Quarter 2023 Financial Results
Published: 2023-08-11 (Crawled : 12:00) - globenewswire.com
PALI | $5.065 -23.26% -30.31% 310K
|
Manufacturing
|
| O: -1.45%
H: 7.51%
C: 4.41%
financial results
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.